Stephen J. Moloney
Keine laufenden Positionen mehr
Profil
Stephen J.
Moloney worked as a European Medical Director at Aspreva Pharmaceuticals Corp.
from 2005 to 2008.
He then worked as a Senior Medical Director at Shire Human Genetic Therapies, Inc. from 2008 to 2014.
In 2014, he became the Executive Medical Director at Aegerion Pharmaceuticals, Inc. until 2015.
From 2015 to 2017, he worked as the Vice President-Medical Affairs at PTC Therapeutics, Inc. He also worked as the Vice President-Global Medical Affairs at Strongbridge Biopharma Plc.
Dr. Moloney earned a doctorate degree from the University of Bristol.
Ehemalige bekannte Positionen von Stephen J. Moloney
| Unternehmen | Position | Ende |
|---|---|---|
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.05.2017 |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2015 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2014 |
Aspreva Pharmaceuticals Corp.
 Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | Corporate Officer/Principal | 01.01.2008 |
| STRONGBRIDGE BIOPHARMA | Corporate Officer/Principal | - |
Ausbildung von Stephen J. Moloney
| University of Bristol | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Strongbridge Biopharma Plc
 Strongbridge Biopharma Plc Pharmaceuticals: MajorHealth Technology Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | Health Technology |
